Boston Scientific is trading 4.04% higher at $44.72 after a broader healthcare-sector rebound, with defensive rotation supporting the group while major indexes decline.
- No new September 14 company-specific catalyst was identified.
- Investors are weighing the September 8 disclosure that a cyberattack disrupted operations and likely caused Boston Scientific to miss 2026 guidance.
- Manufacturing and shipping operations were subsequently restored.